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This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).SUMMARYHere we report the successful generation and long-term expansion of SOX9-expressing CD271+PDGFRa+CD73+ chondrogenic ectome-
senchymal cells from the PAX3/SOX10/FOXD3-expressing MIXL1CD271hiPDGFRaloCD73 neural crest-like progeny of human plurip-
otent stem cells in a chemically defined medium supplemented with Nodal/Activin/transforming growth factorb (TGFb) inhibitor and
fibroblast growth factor (FGF). When ‘‘primed’’ with TGFb, such cells efficiently formed translucent cartilage particles, which were
completely mineralized in 12 weeks in immunocompromized mice. The ectomesenchymal cells were expandable without loss of chon-
drogenic potential for at least 16 passages. They maintained normal karyotype for at least 10 passages and expressed genes representing
embryonic progenitors (SOX4/12, LIN28A/B), cranial mesenchyme (ALX1/3/4), and chondroprogenitors (SOX9, COL2A1) of neural crest
origin (SOX8/9, NGFR, NES). Ectomesenchyme is a source of many craniofacial bone and cartilage structures. Themethod we describe for
obtaining a large quantity of human ectomesenchymal cells will help tomodel craniofacial disorders in vitro and potentially provide cells
for the repair of craniofacial damage.INTRODUCTION
Adult mesenchymal stromal cells (MSCs), defined in vitro
by their potential to contribute to bone-cartilage-fat cell
lineages, are currently used for cell-based bone and carti-
lage therapies because of their ready accessibility. However,
as for other adult stem cells, it is difficult to obtain sufficient
MSCs for treatment. Expansion culture is therefore neces-
sary before transplantation; however, it tends to cause the
loss of long-term viability of the MSCs and their capacity
to differentiate, especially into chondrocytes (Somoza
et al., 2014). Different types of bone and cartilage are
formed most actively during embryonic skeletogenesis
from one of three precursor cell types: paraxial mesoderm,
lateral plate mesoderm, and cranial neural crest. Such em-
bryonic cells and their osteochondrogenic progeny may
be as effective as ormore effective thanMSCs for the regen-
eration of adult bone and cartilage.
The early processes of in vitro differentiation of pluripo-
tent embryonic stem cells (ESCs) mimic those of in vivo
embryogenesis (Nishikawa et al., 2007). Therefore, ESCs
and induced pluripotent stem cells (iPSCs) (collectively
designated pluripotent stem cells or PSCs) would appear
to be thepractical sourceof embryonic precursor cells inhu-
mans. In fact, in vitro induction of osteogenesis and chon-
drogenesis from human PSCs (hPSCs) and mouse (mPSCs)
has been demonstrated by many groups (Nakayama and712 Stem Cell Reports j Vol. 4 j 712–726 j April 14, 2015 j ª2015 The AuthoUmeda, 2011). With the exception of recent reports,
including ours (Craft et al., 2013; Diekman et al., 2012; Na-
kayama et al., 2003; Toh et al., 2009; Umeda et al., 2012;
Zhao et al., 2014), many of the earlier reports described
spontaneous differentiation of hPSCs followed by enrich-
ment of mesenchymal cells by further culturing the prog-
eny in MSC medium. As adult human tissue-derived
MSCs or chondroprogenitors (Koelling et al., 2009; Pit-
tenger et al., 1999), mesenchymal cells derived from
mESCs/iPSCswere able to be expanded extensively; howev-
er, expansion occurred with the loss of their chondrogenic
activity (Bakre et al., 2007; Diekman et al., 2012). Thus far,
the potential benefits of bone and cartilage repair of
hPSC-derived osteochondroprogenitors over those of adult
MSCs, whether in quantity or in quality, have not been
demonstrated, even in vitro (Nakayama and Umeda,
2011). In theory, thewealthof informationon the signaling
mechanisms involved inmouse skeletogenesis should be of
great help in improving the expansion culture methods.
However, the unclear embryonic origins of the chondro-
genic activity developed from PSCs and the undefined con-
ditions used for expansionhavehampered full use of the in-
formation and thereby hindered progress.
A large portion of craniofacial bone and cartilage arises
from osteochondrogenic progeny (i.e., ectomesenchyme)
from cranial neural crest (Santagati and Rijli, 2003), gener-
ated from the junction between anterior neuroectodermrs
and surface ectoderm (Milet and Monsoro-Burq, 2012).
Neural crest cells have been developed from hESCs in
12–28 days of differentiation culture either through neuro-
epithelial intermediates induced by suppression of Nodal/
Activin/transforming growth factor b (TGFb) and bone
morphogenetic protein (BMP) signaling in a defined me-
dium (Chambers et al., 2009; Smith et al., 2008) or directly
by activation ofWNT signaling with suppression of Nodal/
Activin/TGFb signaling (Menendez et al., 2011). Further
differentiation and expansion for 2–3 weeks of such neural
crest cells or earlier neural cells in a serum-containing me-
dium generate MSC-like cells with variable chondrogenic
activity, but never sufficient to reproducibly form cartilage
particles that accumulate proteoglycan-rich, mature
matrices uniformly (hereafter designated ‘‘full-cartilage’’).
Our group has focused on generating and characterizing
paraxial mesodermal progeny from mPSCs/hPSCs, which
are highly chondrogenic (Tanaka et al., 2009; Umeda
et al., 2012; Zhao et al., 2014). In the current study, we
report simple, effective methods for the specification of
neural crest-like progeny from hPSCs and subsequent gen-
eration and expansion of chondrogenically committed ec-
tomesenchymal cells without loss of their chondrogenic
activity over 7–8 weeks in chemically defined media
(CDM). The outcomes were achieved by the control of
fibroblast growth factor (FGF) signaling and Nodal/Acti-
vin/TGFb signaling. We have also defined the cellular
developmental pathway from hPSCs to such ectomesen-
chymal cells using the neural crest markers the low-affinity
nerve growth factor receptor (CD271) (Lee et al., 2007;
Stemple and Anderson, 1992), and the platelet-derived
growth factor receptor a (PDGFRa) (Morrison-Graham
et al., 1992; Weston et al., 2004), and the MSC markers,
CD73 andCD13 (Olivier et al., 2006; Pittenger et al., 1999).RESULTS
Signaling Requirement for Early Development of
Neural Crest-like Progeny from hPSCs
Generation of osteochondrogenic ectomesenchyme from
hPSCs first requires specification of cranial neural crest-
like progeny. In order to reproducibly generate strong
chondrogenic activity from hPSCs, we first optimized the
method for specification of neural crest using CD271 as
the readout. Fluorescence-activated cell sorting (FACS) an-
alyses revealed that when H9 hESCs and BJ5 hiPSCs were
differentiated in CDM using the conventional embryoid
body (EB)-forming culture or 2D differentiation culture in
the presence of SB431542 or other Nodal/Activin/TGFb
signaling inhibitor (e.g., A83-01 or SJN2511), they gener-
ated progeny that expressed CD271 (Figures 1A and S1).
The CD271hi cell population, but not the CD271lo/ prog-Stemeny, also expressed PDGFRa at low levels. Both populations
lacked CD73 and CD13. The effect of SB431542 was dose
dependent at least up to 10 mM (Figure S1D).
The CD271hiPDGFRalo cell development reached a peak
around day 6 of differentiation (Figure S1C), in parallel
with the highest expression of the ‘‘neural crest specifier’’
genes PAX3 and PAX7 (Nelms and Labosky, 2010) (Fig-
ure 1B). In contrast, the neuroectoderm marker SOX1 was
never induced, and the ESCmarkerNANOGwas downregu-
lated. Furthermore, the isolated CD271hi(PDGFRalo)
CD73 progeny had higher levels of SOX10 and FOXD3
transcripts than the CD271lo/(PDGFRa)CD73 cells,
indicating enrichment of the fraction with neural crest-
like progeny (Figure 1D). SOX9 is also implicated in the
specification of cranial neural crest (Nelms and Labosky,
2010) and is expressed in premigratory human neural crest
(Betters et al., 2010). The SOX9 reporter, GFP (Figures 1F
and S1I) and SOX9 transcripts (Figure S1G) were expressed
in the CD271hiCD73 fraction. The PAX3 protein (Fig-
ure 1E) and PAX3 transcript (Figure S1G) were also detected
in the CD271hiCD73 fraction.
Furthermore, insharpcontrast to the resultsobtained from
thehPSCdifferentiation toparaxialmesoderm(Umedaet al.,
2012), when MIXL1 (an early mesendoderm gene)-green
fluorescenceprotein (GFP)knockinhESCs (MIXL1-GFP) (Da-
vis et al., 2008) were differentiated under similar conditions,
no MIXL1-GFP+ progeny developed (Figure 1A). There was
also negligible induction of a second mesendoderm tran-
script,T (Figure S1B) (Umeda et al., 2012). Therefore, neither
CD271hi(PDGFRalo)CD73 nor CD271lo(PDGFRa)CD73
cells were likely to be mesendodermal derivatives.
BMP and WNT are implicated in the neural crest specifi-
cation (Milet and Monsoro-Burq, 2012). As expected, the
BMP inhibitor Noggin suppressed the SB431542-induced
development of the CD271hiPDGFRalo(CD73) neural
crest-like progeny from H9 hESCs (Figure S1E). The WNT
inhibitor FZD also showed an inhibitory effect, consistent
with the findings of Menendez et al. (2011) (Figure S1D).
Interestingly, BMP4 at 10 ng/ml, a concentration sufficient
to induce mesoderm (Wang and Nakayama, 2009), was as
inhibitory as Noggin, and the GSK3 inhibitor that mimics
canonical WNT signaling showed weakly inhibitory effects
(Figure S1E). However, when SOX9-GFP iPSCs were used,
the GSK3 inhibitor was found to enhance the genesis of
CD271hiCD73 cells (Figure S1I).
Thus, inhibition of Nodal/Activin/TGFb signaling with
appropriate levels of BMP and WNT signaling is required
for the effective development of CD271hiPDGFRaloCD73
CD13 neural crest-like progeny from hPSCs (hereafter
called CD271hiCD73 progeny) more quickly than previ-
ously attained (Lee et al., 2010; Menendez et al., 2011),
potentially reflecting the specification of cranial instead
of trunk neural crest cells.Cell Reports j Vol. 4 j 712–726 j April 14, 2015 j ª2015 The Authors 713
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Figure 1. Directed Specification of Neural Crest from hPSCs
(A) FACS analysis demonstrating the SB431542-dependent development of CD271hiPDGFRalo progeny during 2D differentiation of H9 and
MIXL1-GFP hESCs in CDM. SB: 10 mM SB431542.
(B) Time-dependent changes in the gene expression profile during differentiation of H9 hESCs in the presence of SB (n = 3 technical
repeats, mean ± SD).
(C) Isolation of H9-derived CD271hi(PDGFRaloCD73) and CD271lo(PDGFRaCD73) progeny by FACS. (Left) Isotype control.
(D) Real-time RT-PCR analysis with cells from (C) demonstrating enrichment of neural crest-related transcripts in the CD271hiCD73 cell
fraction. Pre, presort cells (n = 3 technical repeats, mean ± SD).
(E) Intracellular FACS staining by anti-PAX3 antibody demonstrating presence of PAX3 protein in the H9-derived CD271hiCD73 cell
fraction. (Upper) Isotype control.
(F) FACS demonstration of SOX9-GFP expression in the CD271hiCD73 progeny in SOX9-GFP hiPSCs differentiated for 6 days.Mesenchymal Cells Derived from the
Nonmesendodermal hESC Progeny by Conventional
Methods Show Weak, Transient Chondrogenic
Activity
The neural crest-like progenywere then directed to commit
to chondrogenic ectomesenchyme. First, using a conven-
tional EB-outgrowth method (Hwang et al., 2006) (Fig-
ure S2A), we generated mesenchymal cells from the
SB431542-treated H9 and MIXL1-GFP hESCs. In knockout
serum replacement-based SR medium or serum-containing
D10 medium, expansion of the outgrowth cells led to714 Stem Cell Reports j Vol. 4 j 712–726 j April 14, 2015 j ª2015 The Authoenhanced expression of CD73 and later CD13, but loss of
the expression of CD271 (Figures S2D and S2E). As we re-
ported previously (Umeda et al., 2012), MIXL1-GFP+ mes-
endodermal progeny were never detected during such
studies (data not shown).
In 3D-pellet culture, the generated mesenchymal cells
gave rise to a particle containing an area that weakly
stained metachromatically (pink to purple) with Toluidine
Blue and immunostained with anti-type II collagen (COL2)
antibody at passage 1 (p1) (Figure S2F) and p2, but not from
p3 to p5. The lack of chondrogenic activity in the primaryrs
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Figure 2. FGF2+SB431542 Generates and Expands SOX9-Expressing CD271+PDGFRa+CD73+ Ectomesenchymal Cells from Unsorted
Nonmesendodermal Progeny
(A) Graphical representation of the experimental procedure. SB, SB431542; F, FGF2; FSB, FGF2+SB431542.
(B) Growth curve of H9 hESC-derived ectomesenchymal cells expanded under F, FSB, and SB conditions (n = 3 independent cultures,
mean ± SD).
(C) FACS analysis demonstrating the effect of FSB on the selective accumulation of CD271+CD73+ mesenchymal. H9 hESCs and BJ5 hiPSCs
were differentiated (Pre) and expanded under the conditions indicated: D10, F, FSB, and FLDN (FGF2+LDN193189). p, passage; isotype
control, Figure S3C.
(D) Micrographs of mesenchymal cells (p4) expanded under F and FSB.
(E) Real-time RT-PCR analysis demonstrating changes in the neural crest gene expression during expansion under F and FSB (n = 3
technical repeats, mean ± SD).outgrowth cells (p0), suggests that a short-term expansion
of the outgrowth cells is required for its development and/
or accumulation. However, as reported by others (Na-
kayama and Umeda, 2011), we did not observe robust
chondrogenic activity leading to a full-cartilage particle,
as found for paraxial mesoderm derived from mPSCs and
hPSCs (Nakayama et al., 2003; Umeda et al., 2012). Thus,
conventional culturemethods failed to generate andmain-
tain strong chondrogenic activity from hPSC-derived neu-
ral crest-like progeny.
Generation and Selective Expansion of
CD271+PDGFRa+CD73+Mesenchymal Cells in CDM in
the Presence of FGF2 and SB431542
Either in a FACS-purified form or in an unpurified mixture
with other nonmesendodermal (i.e., MIXL1) cells, the
CD271hiCD73 neural crest-like progeny failed to adhere
to the culture dish in the absence of fibronectin and grewStempoorly in the medium in which they were specified, i.e.,
CDM plus SB431542 (SB; Figures 2B and S3A). Therefore,
we tested the effects of growth factors, such as FGF2 that
have been used for maintaining neural crest cells (Stemple
andAnderson, 1992) and generating chondrogenic activity
(Abzhanov et al., 2003) in culture, and of other factors,
such as endothelin1, PDGF, and Sonic hedgehog that
have been linked to cranial skeletogenesis and ectomesen-
chymal specification in vivo (Le Douarin and Creuzet,
2009). FGF2 alone significantly increased viability and sup-
ported growth of the neural crest-like progeny on fibro-
nectin but was often associated with significant slowdown
in an early stage of expansion culture. The addition of both
FGF2 and SB431542maintained the growth rate at least un-
til p16 and supported maintenance of the normal karyo-
type at least to p10 (Figure S3B).
Direct expansion of the nonmesendodermal progeny
mix in CDM in the presence of FGF2 and SB431542Cell Reports j Vol. 4 j 712–726 j April 14, 2015 j ª2015 The Authors 715
resulted in accumulation of CD271+PDGFRa+CD73+
mesenchymal cells (Figures 2C, S3, and S4). The cells
were positive for the MSC markers CD105, CD166, CD29,
CD44, and CD56, but negative for MSC markers CD13
and STRO1 (Figures S3D and S3E). In contrast, CD271
expression decreased in the presence of FGF2 alone,
causing the CD271PDGFRa+CD73+ cells to become the
predominant cell population by p3 (Figure 2C). Similar
results were obtained from expansion in D10 medium.
The BMP receptor inhibitor LDN193189 was unable to
replace SB431542. Interestingly, as with EB-outgrowth
cell culture (Figures S2D and S2E), CD13+ cells appeared
later (from p6) under FGF2, but not FGF2+SB431542, con-
ditions (Figure S3D).
The expression of the neural crest genes FOXD3 and
SOX10 was quickly downregulated during expansion un-
der either FGF2 or FGF2+SB431542 conditions, even at
p1, indicating rapid non-neural commitment of the neural
crest-like progeny (Figure 2E) (Nelms and Labosky, 2010).
In contrast, the SOX9 transcript was strongly upregulated
at p1 and maintained over seven passages under
FGF2+SB431542 conditions, whereas the SOX9 transcript
was slightly enhanced at p1 and gradually declined after
p4 under FGF2 conditions.
Our results indicate that activation of FGF signaling and
suppression of Nodal/Activin/TGFb signaling during
expansion of the unsorted nonmesendodermal progeny
of hPSCs selectively lead to the accumulation of SOX9-
expressing CD271+PDGFRa+CD73+CD13 ectomesenchy-
mal cells (hereafter called CD271+CD73+ cells).
The CD271+CD73+ Ectomesenchymal Cells Are
Derived from the CD271hiCD73 Neural Crest-like
Progeny
To determine the cellular origin of the CD271+CD73+ ec-
tomesenchymal cells expanded under FGF2+SB431542
conditions, the CD271hiCD73 and CD271loCD73 prog-
eny, developed from H9 hESCs and BJ5 hiPSCs, were
sorted by FACS (Figures 1C and S1H) and then cultured
in CDM in the presence of FGF2 and one of three
Nodal/Activin/TGFb inhibitors, SB431542, A83-01, or
SJN2511. While FGF2 alone supported the accumulation
of CD271CD73+ cells from either progeny, the FGF2+
SB431542, FGF2+A83-01, and FGF2+SJN2511 conditions
preferentially supported the development of CD271+
CD73+ cells from the sorted CD271hiCD73 neural
crest-like progeny (Figures 3B and S4G). Concentrations
of SB431542 between 1 and 3 mM were sufficient for
the stable maintenance of CD271+CD73+ cells (Fig-
ure S3C). On the other hand, most of the CD271loCD73
progeny did not survive, even under FGF2+SB431542
conditions, and the derived mesenchymal cells were a
mixture of CD271+CD73+ and CD271CD73+ cells (Fig-716 Stem Cell Reports j Vol. 4 j 712–726 j April 14, 2015 j ª2015 The Authoures 3B and S4G) from which the CD271+CD73+ cells
were later lost.
Even at the early p3 stage, SOX9 expression was clearly
observed in the (FGF2+SB431542)-cultured, but not the
FGF2-cultured CD271hiCD73 neural crest-like cells (Fig-
ure 3C). SOX9 expression was not sustained during the
growth of CD271loCD73 cells under either condition.
The nuclear localization of SOX9 protein was also obvious
in 76% (p10) to 85% (p8) of the (FGF2+SB431542)-
expanded CD271+CD73+ cells, of which approximately
20% displayed strong signals (Figure 3D). In support of
this finding, expansion of SOX9-GFP hiPSC-derived
CD271hiCD73 neural crest-like cells under FGF2+
SB431542 for five passages demonstrated that approxi-
mately 20% of the cells remained CD271+GFP+, while the
rest became CD271+GFPlo. No cells became CD271+GFP
(Figure 3E).
Our results indicate that SOX9-positive CD271+CD73+
ectomesenchymal cells were generated and then expanded
from the CD271hiCD73 neural crest-like progeny of
hPSCs in CDM in the presence of FGF2 and Nodal/Acti-
vin/TGFb inhibitors and that changes to this growth condi-
tion led to the generation of SOX9-negative CD271CD73+
mesenchymal cells.The CD271+CD73+ Cells Maintain Measurable
Chondrogenic Activity during Expansion
Since the CD271+CD73+ ectomesenchymal cells main-
tained in FGF2+SB431542 express SOX9, we sought to
demonstrate that they were chondrogenic using 2Dmicro-
mass culture. Under the condition in which PDGF-BB was
added to the chondrogenesismediumonday 0 and then re-
placed with TGFb3 on day 6, which was supplemented
with BMP4 on day 10 (hereafter designated as PDGF/
TGFb/BMP condition) (Umeda et al., 2012),
CD271+CD73+ cells gave rise to acid Alcian Blue-positive
cartilage nodules, the capacity of which lasted at least until
p10 (i.e., 5 weeks) of expansion culture (Figures 3F and
S4A). In contrast, the CD271CD73+ cells generated and
maintained under FGF2 conditions showedweak chondro-
genic activity as early as p3. The SB431542-cultured cells
showed no chondrogenic activity and ceased to grow at p2.Brief Treatment with TGFb Facilitates Formation of
Macroscopic Cartilage Particle Formation from the
CD271+CD73+ Cells
The ectomesenchymal cells expanded in CDM in the pres-
ence of FGF2 or FGF2+SB431542 were subjected to 3D-pel-
let culture under the PDGF/TGFb/BMP condition. The early
(p2) FGF2-expanded cells formed a large cartilage particle
that stained metachromatically (pink to purple) with Tolu-
idine Blue, but then lost such chondrogenic activity byrs
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Figure 3. The SOX9-Expressing CD271+CD73+ Ectomesenchymal Cells Are Chondrogenic and Derived from the CD271hiCD73Neural
Crest-like Cell Fraction
(A) Graphical representation of the experimental procedure.
(B) FACS analysis of the sorted CD271hiCD73 (CD271hi) and CD271loCD73 (CD271lo) progeny, expanded under F, FSB, FSJN
(FGF2+SJN2511), and FA83 (FGF2+A83-01) for three passages.
(C) Real-time RT-PCR with cells in (B) demonstrating SOX9 expression specifically maintained in the FSB-expanded CD271hi cells. sort, pre-
expanded cells (n = 3 technical repeats, mean ± SD).
(D) Immunofluorescence detection of SOX9 protein in the FSB-expanded CD271hi cells. Pink, SOX9; blue (nucleus), DAPI; graph, the value
of % SOX9+ nuclei was the average of scoring from four areas (n = 4 technical repeats, mean ± SD); ++, strong signal; +, weaker signal;
isotype control, Figure S4J.
(E) SOX9-GFP expression in the FSB-expanded CD271hi cells. SOX9-GFP hiPSCs were differentiated, and the CD271hiCD73 progeny were
isolated and expanded under FSB for five passages as in (A) and then FACS analyzed (Figure S3H). H9 hESC-derived, FSB-expanded cells in
(B) were used as the GFP-negative control.
(F) Chondrogenic activity of the CD271hi or CD271lo progeny maintained under FSB. Cells were grown under FSB and F conditions for five
passages and subjected to 2D-micromass cultures, followed by Alcian Blue staining and quantification. *p < 0.05 (n = 3 independent
cultures, two masses/culture, mean ± SD).p4–p5 (Figures 4A and 4C), in keeping with the loss of the
CD271+ cell population (Figures 2C and S3D).
On the other hand, the (FGF2+SB431542)-expanded cells
did not form a particle when subjected directly to pellet
culture (no pellet, Figure 4B), suggesting that (FGF2+
SB431542)-expanded cells are defective in the induction
of mesenchymal condensation, a prerequisite for cartilage
formation. Supporting this suggestion, 2D-micromass cul-
ture demonstrated that inclusion of SB431542 until the
point of induction of chondrogenesis using TGFb3 and
BMP4 severely inhibited or delayed the formation of carti-
lage nodules (Figures S4A and S4B). Thus, suppression ofStemNodal/Activin/TGFb signaling allows the CD271+CD73+
cells to grow but not to initiate chondrogenesis under the
action of TGFb and BMP.
A brief treatment (‘‘priming’’) with TGFb is known to
commit mouse neural crest stem cells to mesenchymal lin-
eages (John et al., 2011). Therefore, we reasoned that stim-
ulation with TGFb before pellet culture might be required
for efficient cartilage particle formation. When the
(FGF2+SB431542)-expanded cells were passaged once
into CDM containing FGF2+TGFb3 (FT), cultured for 3 to
4 days to confluence, and then subjected to 3D-pellet cul-
ture, large translucent full-cartilage particles filled withCell Reports j Vol. 4 j 712–726 j April 14, 2015 j ª2015 The Authors 717
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Figure 4. Pretreatment with TGFb Facilitates Cartilage Particle Formation from the FSB-Expanded Ectomesenchymal Cells
(A and B) Cartilage particle formation from the H9 hESC-derived ectomesenchymal cells maintained under F (A) or FSB (B) by 3D-pellet
culture. Toluidine Blue staining (purple) of sections of the cartilage particles, except for (Bvi), which is COL2 immunostained (brown).
Some cultures were passaged once or twice (p2) to FT (CDM plus FGF2+TGFb3) (Aiii, Bi, Bii, Bv, Bvi), or D10 (Aiv, Biii, Biv), prior to pellet
culture.
(C) Capacity of sGAG production in cartilage particles. The ectomesenchymal cells cultured as indicated (/FT, passage to FT) were
subjected to pellet culture and total DNA and sGAGs were quantified. Negative control: undifferentiated ESCs. *p < 0.05 (n = 3 independent
cultures, one pellet/culture mean ± SD).
(D) Upregulation of N-cadherin surface expression on the FSB-expanded ectomesenchymal cells during FT treatment. The ectomesen-
chymal cells maintained under F (Fp2) and FSB (FSBp5) were either passaged to FSB (/FSB), FT (/FT, FTp2), or D10 (/D10) or not
passaged (Fp2), and then FACS analyzed.
(E) Effect of FT treatment on SOX9 protein expression. FSB-expanded p7 ectomesenchymal cells followed by FT culture (i.e., p8) were
treated and analyzed as in Figure 3D. Graph, n = 4 technical repeats, mean ± SD. Isotype control, Figure S4J.
(F) Real-time RT-PCR analysis for investigating the effect of FT treatment on SOX9 gene expression (n = 3 technical repeats, mean ± SD).matrices that stained metachromatically with Toluidine
Blue and immunostained with the COL2 antibody were
generated effectively (Figures 4Bi, 4Bv, 4Bvi, S4F, and
S4H). The SB431542-dependent maintenance of chon-
drogenic activity during expansion culture was con-
firmed by the quantitative comparison of sulfated glycos-
aminoglycan (sGAG) levels in 24 days of pellet culture
using ectomesenchymal cells maintained under FGF2+
SB431542 (FSBp11/FT) and under FGF2 alone (Fp4)
(Figure 4C).718 Stem Cell Reports j Vol. 4 j 712–726 j April 14, 2015 j ª2015 The AuthoWhen FGF2+TGFb3 pretreatment was extended for a few
more passages (FTp2), the cells maintained their particle-
forming capability but gradually lost their chondrogenic
potential, resulting in particles with a small cartilaginous
area (Figure 4Bii). Pretreatment with D10 medium also
induced pellet-forming activity in the (FGF2+SB431542)-
expanded cells, which led to a full-cartilage particle (Fig-
ure 4Biii), but further maintenance in D10 completely
suppressed chondrogenic activity (Figure 4Biv). Neither
pretreatmentwas able to recover lost chondrogenic activityrs
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Figure 5. The Long-Term Expanded Ecto-
mesenchymal Cells Are Still Dependent
on FSB
(A) SB431542-dependent maintenance of
CD271 expression. Ectomesenchymal cells
maintained under FSB (p10) were either
passaged one to three times to FSB again
(p11, p14), or to FGF2 (/F, Fp3) and then
FACS analyzed.
(B) Maintenance of sGAG production ca-
pacity. The ectomesenchymal cells main-
tained under FSB for 11–16 passages
followed by FT treatment, and the freshly
isolated chondrogenic paraxial mesoderm
(PM) (Umeda et al., 2012) were subjected to
pellet culture. The capacity for sGAG pro-
duction is displayed as in Figure 4C. Nega-
tive control, hESCs; positive control, bovine
articular cartilage (n = 3 technical repeats,
mean ± SD).
(C) ‘‘Full-cartilage’’-forming capacity re-
mained in the FSB-expanded p13 ectome-
senchymal cells derived from CD271hiCD73
H9 progeny. Toluidine Blue staining.
(D) SB431542-dependent maintenance of
chondrogenic activity. The p10 ectome-
senchymal cells were passaged to either FSB for four passages (FSBp14) or F for two passages (/Fp2) and then subjected to FT treatment
and 3D-pellet culture. The capacity for sGAG production is displayed as in (B). *p < 0.05 (nR 3 independent cultures, one pellet/culture,
mean ± SD).
(E) Real-time RT-PCR analysis for investigating the effect of FSB on maintaining SOX9 expression (n = 3 technical repeats, mean ± SD).in FGF2-expanded cells (Figures 4Aiii and 4Aiv). A brief
TGFb pretreatment thus seemed to enhance the
condensing capacity but not the chondrocyte-forming
ability of the expanded ectomesenchymal cells. In support
of this observation, the proportion of cells expressing
SOX9 protein increased only slightly from 76%–83% (Fig-
ure 3D) to 97% (Figure 4E), and the transcription levels of
SOX9 (Figure 4F), SOX5, and SOX6 (data not shown) were
unaltered by the 4-day FGF2+TGFb3 treatment.
In contrast, FGF2+TGFb3 treatment (/FT, Figure 4D) led
to dramatic downregulation of the expression of CD271 in
3 to 4 days and complete loss of expression during the sub-
sequent culture for two passages (/FTp2). A similar
change was observed with D10 treatment. Since the
short-term (FGF2+TGFb3)-treated cells effectively formed
cartilage particles (Figures 4Bi, 4Biii, and 4Bv), the reduc-
tion/loss of CD271 expression may be an early indicator
that chondrogenic activity will be lost later.
TGFb upregulates the production of extracellular matrix
proteins and cell surface molecules such as fibronectin,
N-cadherin, and N-CAM (CD56), which are involved in
the initiation of precartilaginous mesenchymal condensa-
tion (Chimal-Monroy and Dı´az de Leo´n, 1999). CD56
but not N-cadherin was expressed on most of theStem(FGF2+SB431542)-expanded ectomesenchymal cells (Fig-
ures 4D and S3E). However, treatment with FGF2+TGFb3
or D10 resulted in the upregulation of N-cadherin. In addi-
tion, the (FGF2+SB431542)-expanded cells exposed to
FGF2+TGFb3 for two passages and the FGF2-expanded cells
(Fp2) accumulated distinct N-cadherinlo and N-cadherin+
populations. Together the results support the hypothesis
that brief pretreatment with TGFb enhances the precartila-
ginous condensing capacity of the ectomesenchymal cells
expanded under FGF2+SB431542 conditions.
Property of the CD271+CD73+ Cells Maintained under
FGF2+SB431542 for an Extended Period
Since CD271+CD73+ ectomesenchymal cells maintained
under FGF2+SB431542 for a long time might select a rare
‘‘permanent CD271+ chondrogenic cell’’ from the original
neural crest cell population, late-passage (p10) cells were
subjected to medium change to CDM with FGF2 alone.
All cells started losing the CD271 expression in FGF2 and
nearly 95% became CD271CD73+ by passage 3 (Fig-
ure 5A). Those maintained in FGF2+SB431542 for four
more passages were still CD271+CD73+, suggesting that
maintenance of CD271 surface expression remained
dependent on the presence of SB431542.Cell Reports j Vol. 4 j 712–726 j April 14, 2015 j ª2015 The Authors 719
Furthermore, when 3D-pellet culture was performed, the
(FGF2+SB431542)-expanded ectomesenchymal cells main-
tained their chondrogenic activity during further expan-
sion (p11–16), as judged by the accumulation of sGAGs in
the developed cartilage particles (Figure 5B), and the ‘‘full
cartilage’’-forming activity was preserved at least to p13
(Figure 5C). Interestingly, such chondrogenic activity was
indistinguishable from that of theKDRPDGFRa+ chondro-
genic paraxial mesodermal cells (PM) we previously re-
ported (Umeda et al., 2012). However, even two passages
without SB431542 caused the p10 cells to begin showing
signs of decline in their capacity to generate similar chon-
drocytes in quantity and quality (/Fp2, Figures 5D and
5E). These results indicate that expansion under
FGF2+SB431542 conditions does not select a permanently
chondrogenic CD271+ cell type and that continuous sup-
pression of the endogenous Nodal/Activin/TGFb signaling
is necessary for preventing the loss of chondrogenic activity
and CD271 expression for an extended period.
The Presence of SB431542 Maintains Expression of
Genes Representing ‘‘Proliferative’’ and ‘‘Primitive’’
Stages of Differentiating Neural Crest
Weperformedgenome-wide, comparative transcriptomean-
alyses to elucidate themolecular basis of the effect of Nodal/
Activin/TGFb signaling-suppression on the maintenance of
the proliferative and chondrogenic properties of the
CD271+CD73+ ectomesenchymal cells. TheCD271hiCD73
neural crest-like progeny of H9 hESCs were isolated and
expandedunder FGF2+SB431542 conditions for six to seven
passages (FSB, Figure 6). In some cases, the culture condition
was shifted to the FGF2 condition from p4 (FSB/F). As a
control, the CD271hiCD73 cells were cultured from the
outset under FGF2-conditions (F) for six passages.
The overall mRNA profiles of the three resultant cell pop-
ulations demonstrated that (FGF2+SB431542)-expanded
neural crest cells are distinct from both FGF2- and
(FGF2+SB431542/FGF2)-expanded cells (Figures 6A and
6B), whereas little distinction was found between the last
two. However, the possibility remained that the FGF2-
cultured neural crest cells are different types of cells from
(FGF2+SB431542)-expanded cells. Therefore, to investigate
theeffect ofTGFb suppression, furthercomparativeanalyses
focused on (FGF2+SB431542)- and (FGF2+SB431542/
FGF2)-cultured cells.
First, gene ontology (GO) analysis suggested that
(FGF2+SB431542)-expanded cells would likely be involved
in ‘‘DNA replication,’’ ‘‘mitotic cell cycle,’’ and ‘‘cell divi-
sion’’ (Figure 6D), while (FGF2+SB431542/FGF2)-
cultured cells seemed to have the property of differentiated
cells and would likely be involved in ‘‘cell adhesion,’’
‘‘angiogenesis,’’ and/or ‘‘skeletal system development.’’
Furthermore, as for the predicted developmental poten-720 Stem Cell Reports j Vol. 4 j 712–726 j April 14, 2015 j ª2015 The Authotials, (FGF2+SB431542)-expanded cells still showed rele-
vance to ‘‘peripheral nervous system development,’’ ‘‘mela-
nocyte differentiation,’’ and/or ‘‘eye development’’
(Figure 6D), although essential genes such as SOX10,
ASCL1-4, NEUROD1/2/4/6, NEUROG1-3, OLIG1-3, MITF,
and PAX6 (Nelms and Labosky, 2010) were either not
(yet) expressed or expressed at very low levels (FPKM %1;
data not shown). In contrast, (FGF2+SB431542/FGF2)-
cultured cells seemed to be associated more with ‘‘ossifica-
tion,’’ ‘‘odontogenesis,’’ and ‘‘embryonic vicerocranium
morphogenesis.’’ In addition, consistent with the removal
of SB431542, enhancement of ‘‘TGFb receptor signaling’’
was suggested.
Comparison of genes in either cell population that
showed more than a 2.5-fold difference in expression level
(Figure 6C; Tables S3 and S4) supported the GO analysis in
that genes preferentially expressed under FGF2+SB431542
conditions represented many, if not all, aspects of neural
crest (stem) cells and primitive ectomesenchyme. Such
genes included LIN28A/B, TRIM71(LIN41) and MYCN (Ec-
sedi and Grosshans, 2013; Rehfeld et al., 2015), TWIST1/
2, ALX1/3/4, SOX8/9 (Nelms and Labosky, 2010), and NES
as well as stem cell factor receptor (KIT). In contrast,
TGFB3 and other TGFb-induced genes such as DCN and
THBS1/2 were induced when SB431542 was removed
(FSB/F). Interestingly, the FGF2+SB431542 condition
supported the expression of COL2A1, the type II collagen
gene, SOX9 regulator genes such as MAF (Huang et al.,
2002) and ZBTB16 (Liu et al., 2011), and LBH (Powder
et al., 2014), while the FGF2+SB431542/FGF2 condition
induced COL1A1/1A2 and RUNX1/2 expression, support-
ing their predicted ‘‘ossification’’ function. Consistent
with FACS analyses, expression of NGFR (CD271), the cell
surface marker gene for neural crest, was found to be sup-
ported under FGF2+SB431542 conditions, and ANPEP
(CD13) was induced under FGF2+SB431542/FGF2. On
the other hand, among genes commonly expressed in cells
cultured under both conditions, the presence of SOX4 and
SOX12 supports the likelihood that both are embryonic
neural/mesenchymal progenitor cells (Bhattaram et al.,
2010).
In Vivo Stability of the Cartilage Particle Developed
In Vitro with the CD271+CD73+ Cells: A Comparative
Analysis
Cartilage particles generated under standard ‘‘PDGF/TGFb/
BMP’’ conditions (Umeda et al., 2012) with the
CD271+CD73+ ectomesenchymal cells, derived either
from a mixture of the 6-day differentiated H9 hESCs or
from the FACS-isolated CD271hiCD73 neural crest-like
progeny (Figures 7C and 7D), were all mineralized after
subcutaneous transplantation into immunocompromized
mice for 8–12 weeks (black area with von Kossa staining),rs
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Figure 6. Comparative Transcriptome Analysis of Ectomesenchymal Cells Using the RNA-seq Technology
(A) Heat map of the top 250 genes, which are differentially expressed among the three groups. Lanes 1–3: ‘‘FSB’’; lanes 4, 5, 8: ‘‘F’’; lanes 6,
7, 9: ‘‘FSB/F.’’
(B) Principal component analysis of the expression pattern of protein-coding genes among the three groups. Blue, ‘‘FSB’’; red, ‘‘F’’; green,
‘‘FSB/F.’’
(C) Selected list of culture condition-specific genes and common genes. Genes that gave a p < 0.05 were picked from Tables S3 and S4
except for few with * that gave slightly more variations (0.05 < p < 0.1). ND, not determined.
(D) GO analysis. Selected GO categories from Table S1 (upper) and a selected list of development-related GO terms from Table S2
(lower).
(E) RT-PCR confirmation of the relative gene expression levels predicted by the FPKM values (n = 3 independent cultures, mean ± SD).implying the capacity of the CD271+CD73+ cell to induce
endochondral ossification. Consistently, the detection of
RUNX2 transcript (2D-micromass culture, Figure 7E) and
COL10A1 transcript (3D-pellet culture, Figure 7F) during
chondrogenesis suggested that the ectomesenchymal cell-
derived chondrocytes matured into hypertrophic
chondrocytes.
Such a property of the ectomesenchymal cells might
reflect a more general property of hPSC-derived chondro-
genic cells. Therefore, we also examined the cartilage
particles produced by the hPSC-derived KDRPDGFRa+
chondrogenic paraxial mesodermal progeny (UmedaStemet al., 2012). First, we significantly improved the yield of
KDRPDGFRa+ progeny expressing higher levels of
MEOX1, TCF15, as well as UNCX (Figure S5) by replacing
BIO with CHIR99021 and inhibiting FGF signaling with
PD173074 at a later stage of differentiation. Next, carti-
lage particles were generated and transplanted subcutane-
ously. The transplanted particles were mineralized at the
periphery, but four of six particles stably maintained in-
ternal unmineralized cartilaginous areas even after
12 weeks (Figure 7A). In some case, the whole cartilagi-
nous particles remained unmineralized (Figure 7B). These
results indicate that the strong tendency of terminalCell Reports j Vol. 4 j 712–726 j April 14, 2015 j ª2015 The Authors 721
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Figure 7. In Vivo Stability of Cartilage Particles Developed with the CD271+CD73+ Ectomesenchymal Cells
(A–D) In vivo maturation of cartilage particles developed with the FSB-expanded CD271+CD73+ ectomesenchymal cells (C and D),
generated from H9 hESC-derived CD271hiCD73 neural crest-like progeny in comparison with those developed with the freshly isolated
KDRPDGFRa+ paraxial mesoderm, derived from H9 hESCs under the CHIR99021-based 4i+P conditions (A) and from HES3 hESCs under the
BIO-based 2i condition (B) (Umeda et al., 2012). Cartilage particles were transplanted into NSG mice (A, C, and D) and NODScid mice (B)
subcutaneously for 12 weeks, recovered, fixed, sectioned, and stained with Toluidine Blue (cartilaginous area is in purple) and von Kossa
(bony area is in black).
(E and F) Cartilage gene expression during chondrogenesis cultures. The FSB-expanded p7 cells were subjected to 2D-micromass culture (E)
or 3D-pellet culture (F) and then real-time RT-PCR (n = 3 technical repeats, mean ± SD).
(G and H) Immunostaining with anti-human mitochondria (hMit) antibody. Sections of a bony particle made in (C) and (D) were stained
with H&E (G) or stained with hMit antibody (pink, G and H) and anti-type I collagen (COL1) antibody (green, H), followed by counter-
staining with DAPI (blue). Negative controls, Figures S4K and S4L.maturation in vivo is not a general property of the
hPSC-derived chondrogenic progeny. The neural crest-
derived ectomesenchymal cells may innately possess
such a property or may have been primed for it during
expansion.
Endochondral ossification would replace the trans-
planted cartilage (consisting of human chondrocytes)
with bone tissuemade by osteoblasts and osteocytes ofmu-
rine origin.We therefore addressed the question ofwhether
the donor human chondrocytes completely disappeared
from the bony particles generated in 12weeks. As expected,
immunohistochemical analyses revealed that the large hy-
pertrophic chondrocytes showed human-specific signals
(Figure 7G). Interestingly, human cells were also detected
in a marrow-like space and around the COL1-positive722 Stem Cell Reports j Vol. 4 j 712–726 j April 14, 2015 j ª2015 The Authobone pieces (Figure 7H), suggesting that the transplanted
cartilage particles may contain cells with osteoblastic/
osteocytic potential.DISCUSSION
We have established a novel serum-free culture method for
generating and expanding CD271+CD73+SOX9+ chondro-
genic ectomesenchymal cells from hPSC-derived,
CD271hiCD73 neural crest-like progeny. The differentia-
tion pathways from hPSCs to chondrocytes via chondro-
genic ectomesenchymal cells postulated from this study
are summarized in the Graphical Abstract. Under optimal
conditions, the generation of neural crest-like progenyrs
fromhPSCs in CDMwas achievedmore quickly than previ-
ously reported, and the resultant ectomesenchymal cells
displayed long-term chondrogenic activity.
Quantitative data on the efficiency of genesis of SOX9-
expressing chondroprogenitors from hESCs were first
shown by Oldershaw et al. (2010). Under their conditions
in which hESC differentiation is directed initially to meso-
derm then toward chondrocytes, approximately 8.5 chon-
droprogenitors of 75%–97% SOX9+ are produced per hESC
by day 14 of differentiation. In contrast, while only about
0.6 CD271hiCD73 neural crest-like progeny were gener-
ated per hPSC by day 6 of differentiation in CDM plus
SB431542 (data not shown), our method for neural crest-
like cell culture in CDM in the presence of FGF2+SB431542
led to 19 to 38 CD271+CD73+ chondroprogenitors per
hPSC by day 14 (Figure S3A). Approximately 76%–85% of
these cells continued to express SOX9 protein on days
27–33 (p8–p10), a proportion that increased slightly to
about 97% after 3 days of treatment with FGF2+TGFb3.
Further expansion yielded approximately 13 107 chondro-
genic ectomesenchymal cells per hPSC by day 51 (p16, 24
population doublings). Thus, the method described here
allows human chondrogenic cells to expand for an
extended period without the loss of purity and chondro-
genic activity, resulting in a much larger yield of chondro-
progenitor cells (although not homogenous) from hPSCs
than previously attained.
The effect of SB431542 on expansion of endothelial pro-
genitors derived from mouse and human ESCs has also
been reported (James et al., 2010; Watabe et al., 2003). A
lack of Nodal/Activin/TGFb signaling may generally pro-
mote proliferation and prevent terminal differentiation of
embryonic stem/progenitor cells. In this respect, the ways
in which FGF2+SB431542 helps to maintain SOX9 and
CD271 while suppressing N-cadherin expression during
expansion of the chondrogenic CD271+CD73+ cells and in
which CD271hiCD73 neural crest-like cells are directed to
give rise to such cells are interesting topics for future study.
In this respect, comparative transcriptome analysis has re-
vealed that the CD271+CD73+ cells accumulated under
FGF2+SB431542 conditions possess a similar mRNA profile
to primitive neural crest/ectomesenchymal cells, although
they lacked SOX10 expression, which is critical for neural
and melanocytic lineage commitment. Thus, suppression
of Nodal/Activin/TGFb signaling does not seem to freeze
the developmental stage of the hPSC-derived neural crest
during expansion. Such suppression may instead simply
support the high proliferative potential of the cells as well
as the expression of SOX9 (andCOL2A1), and therebymain-
tain chondrogenic activity. SOX9 expression initiated at the
specification and premigratory stages is transient in trunk
neural crest but persists in cranial neural crest (Cheung and
Briscoe, 2003; Cheung et al., 2005; McKeown et al., 2005).StemThe chondrogenic CD271+CD73+ ectomesenchymal cells
that maintain SOX9 transcription and translation (SOX9-
GFP+/lo) may therefore represent proliferating cranial neural
crest, with a slight commitment to non-neural lineages.
Genesis of MSC-like cells from hESCs directly or via neu-
roectoderm specification has been demonstrated (Cham-
bers et al., 2009; Mahmood et al., 2010). As shown in Fig-
ure S4D, the colonogenic (CFU-F) activity, representing
self-renewal activity of MSCs, emerged as early as p2 of
the expansion culture under FGF2 alone (i.e., in CD271
CD73 cells) or FGF2+SB431542 (i.e., in CD271+CD73+
cells). However, we were unable to demonstrate significant
adipogenic or osteogenic activity in either cell type (data
not shown), although theGOanalysis predicted osteogenic
activity in cells generated under FGF2 (data not shown) and
FGF2+SB431542/FGF2 conditions. This discrepancy may
be due to some degree of heterogeneity in the cell types
generated under these conditions or to the assay method
employed, which is widely used for MSCs (Pittenger et al.,
1999), but is less well validated for mesenchymal cells
derived from human neural crest. Furthermore, the
FGF2+SB431542 conditions applied to the expansion cul-
ture of mouse bone marrow MSCs resulted in inhibition
of proliferation and promotion of adipocytic differentia-
tion (data not shown). The CD271+CD73+ ectomesenchy-
mal cells are therefore very likely not to be MSCs, although
the possibility that they are derived from an MSC-like pre-
cursor has not been excluded.
Thus, hPSC-derived chondrogenic ectomesenchymal
cells are amenable to large-scale production in CDM
without loss of activity. Although some hESC-derived neu-
ral crest stem cells are known to self-renew in culture for an
extended period, during which they maintain the capacity
to produce multipotential MSC-like activity (Menendez
et al., 2011), no previous reports have described a method
as simple and effective as ours for generating large quanti-
ties of (osteo)chondrogenically committed mesenchymal
cells under clinically applicable, defined conditions. There-
fore, the chondrogenic ectomesenchymal cells produced
by the culture technology described are set to become a
competitive alternative to adult MSCs, especially for
craniofacial regenerative therapy. Moreover, taking advan-
tage of high yields of chondroprogenitor cells, we have suc-
cessfully modeled neonatal-onset multisystem inflamma-
tory disease by applying our method to patient-derived
iPSCs (Yokoyama et al., 2015).EXPERIMENTAL PROCEDURES
Cells
H9 (WA09), HES3 (ES03),MIXL1-GFPhESCs, and the humanfibro-
blast-derived iPSC line, BJ5, were maintained on feeder cells
as described (Umeda et al., 2012). The SOX9-GFP hiPSCCell Reports j Vol. 4 j 712–726 j April 14, 2015 j ª2015 The Authors 723
(CY2-SOX9-2A-ZsGreen-2A-Puro) line from NIH was maintained
feeder free in E8 medium.
Neural Crest Cell Differentiation from hPSCs
For generating neural crest-like progeny, H9 hESCs and BJ5 hiPSCs
were transferred to gelatin-coated dishes and cultured feeder free in
the differentiation medium: CDM supplemented with SB431542.
The SOX9-GFP hiPSCs were directly induced to differentiate by
changing the medium to differentiation medium.
Paraxial Mesoderm Generation from hESCs
The hPSCs were differentiated as described (Umeda et al., 2012)
(‘‘2i’’ condition) or using improvements involving CHIR99021,
Noggin, PD173074, and PDGF with or without SB431542 (‘‘3i+P’’
or ‘‘4i+P,’’ Figure S5).
Flow Cytometry
FACS analysis and cell sortingwere performed as described (Umeda
et al., 2012). Intracellular staining for FACS analysis using mouse
anti-PAX3 monoclonal antibody was performed according to the
manufacturer’s recommendations.
Ectomesenchymal Cell Genesis and Expansion
The differentiated hPSCs before and after sorting for
CD271hiCD73 were plated onto fibronectin-coated dishes and
cultured in CDM supplemented with FGF2 and/or SB431542 (or
other small molecules) or in the serum-containing D10 medium.
Immunofluorescence Detection of SOX9
The CD271hiCD73 neural crest-like progeny were cultured in an
eight-well chamber slide for 3 days in CDM containing either
FGF2+SB431542 or FGF2+TGFb3 and immunostained with the
anti-hSOX9 polyclonal antibody.
Chondrogenesis Assays
2D-micromass culture and 3D-pellet culture were performed and
analyzed as described (Nakayama et al., 2003; Tanaka et al., 2009;
Umeda et al., 2012).
Quantification of Sulfated Glycosaminoglycans
DNAs and sulfated glycosaminoglycans (sGAGs) from micro-
masses and cartilage particles were isolated, quantified, and
analyzed as described (Zhao et al., 2014).
Subcutaneous Transplantation and
Immunohistological Analysis
Cartilaginous particles were transplanted under the dorsal skin of
NODScid or NODScid Il2rg/ (NSG) mice for 8–12 weeks and
analyzed as described (Zhao et al., 2014). To detect remaining hu-
man cells, the fixed particles were first decalcified and then paraffin
embedded, sectioned, and stained with the mouse antihuman
mitochondria monoclonal antibody.
Gene-Expression Profiling
Total RNAs were isolated and reverse transcribed (RT), and real-
time PCRwas performed using the TaqmanGene ExpressionAssay.724 Stem Cell Reports j Vol. 4 j 712–726 j April 14, 2015 j ª2015 The AuthoThe results were displayed as described (Zhao et al., 2014). RNA
sequencing was performed on an Illumina HiSeq 1500. Sequenced
reads were deposited to Gene Expression Omnibus (GSE64752)
and mapped against the human reference genome (GRCh37).
Expression levels were calculated as fragments per kilobase of
exon per million mapped fragments (FPKMs) (Tables S1, S2, S3,
and S4).SUPPLEMENTAL INFORMATION
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